T he prevalence of advanced heart failure has continued to increase in the United States and worldwide, and left ventricular assist devices (LVADs) are being implanted more frequently for the treatment of end-stage congestive heart failure (CHF). 1 The HeartMate II (HMII), the most commonly used continuous flow LVAD (cfLVAD), has been shown to improve survival and functional status in patients with advanced heart failure and is used as bridge to transplantation (BTT), bridge to recovery, and destination therapy (DT). 2, 3 As the number of patients living with LVADs and support time increase, it becomes paramount to manage complications associated with these devices properly.
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Ventricular arrhythmias (VAs) are common in patients with cfLVADs, occurring in 20% to 50% of patients with the majority of episodes arising in the first 30 days after implant. [4] [5] [6] [7] [8] However, the clinical consequences of these episodes remain unclear. While some patients may experience hemodynamic compromise attributable to the deleterious effects on the right ventricle, others tolerate extended episodes of VA without symptoms or significant change in LVAD output. Furthermore, the impact of VAs on mortality in patients with an LVAD is uncertain. Previous studies in patients with pulsatile LVADs suggested increased mortality associated with VAs, 9, 10 but the few available studies in patients with cfLVADs are contradictory. 6, 7 Because of the unclear clinical significance of VAs in patients with an LVAD, the role of implantable cardioverterdefibrillators (ICDs) in this patient population remains undefined. The majority of patients who receive an LVAD already have an ICD, but the effectiveness of ICDs in reducing mortality in these patients has not been established. As such, we sought to examine the clinical significance of VAs and the impact of ICDs on mortality in patients with cfLVADs.
at the time of HMII implantation were included if the RVAD was subsequently explanted and the patient survived the index admission. Patients were followed up until they reached one of the following end points: death, transplantation, HMII explantation, end of follow-up period (October 31, 2012), or loss to follow-up. The Institutional Review Board of the Mount Sinai School of Medicine approved this study.
Ventricular Arrhythmias
Electrocardiograms, telemetry strips, device interrogations, and progress notes were reviewed for the occurrence of VAs after HMII implantation. VAs were defined as sustained ventricular tachycardia lasting for >30 seconds or any episodes of ventricular fibrillation. Nonsustained ventricular tachycardia was not included. Early VA was defined as VAs occurring ≤30 days after HMII implantation, and late VA was defined as VAs occurring after 30 days. The clinical presentation (ie, symptoms, hemodynamics) and cycle length of each VA episode were noted. There was not a standard protocol in place for the treatment of VAs, but antiarrhythmic drugs (AADs) with electrical cardioversion were frequently used in the acute setting. The continuation of AADs was left to the discretion of the heart failure specialist, usually in consultation with an electrophysiologist. Finally, the occurrence of hospitalizations for CHF was recorded to examine the relationship between VAs and CHF.
ICD Status
The ICD status of each patient pre-LVAD was reviewed. ICDs were deactivated during LVAD implantation and reactivated postoperatively per protocol. LV pacing in patients with a cardiac resynchronization device remained deactivated. Otherwise, ICD settings post-LVAD were restored to pre-LVAD settings or left to the discretion of the consulting electrophysiology physician. Post-LVAD, patients whose ICD remained active or had a new ICD implanted were analyzed in the ICD group. Patients without an ICD pre-LVAD and those who had their ICD inactivated or explanted post-LVAD were placed in the no ICD group.
Survival Analysis
To examine the effect of VAs and ICDs on survival in patients with the HMII, patients who died within 30 days of implantation were excluded because these deaths are most often attributable to perioperative complications. The primary outcome was all-cause mortality, and patients were censored if they underwent transplantation, reached the end of the study, or were lost to follow-up.
Statistical Analysis
Categorical variables were evaluated using the χ 2 test or Fisher exact test. Continuous variables were analyzed with the t test. For multivariable regression analysis, variables that had P<0.15 during univariable analysis were included in the multivariable model. The predictors of post-LVAD VAs were determined using multivariable logistic regression, and the effect of VAs and ICDs on survival was analyzed using multivariable Cox proportional hazards regression. Survival curves were constructed using the Kaplan-Meier method, and statistical significance was determined using the log-rank test.
All P values were 2-tailed, and the level of significance for all P values was <0.05. Confidence intervals (CIs) were computed at the 95% confidence level. All statistics were computed using Stata 12 (StataCorp, College Station, TX).
Results

Demographics
During the study period, 108 patients received the HMII. Two patients who received a concomitant RVAD and died before RVAD explantation were excluded, leaving 106 patients in the total cohort. The baseline characteristics of the cohort are listed in Table 1 . Overall, the majority of patients were male (82.1%), had a nonischemic cardiomyopathy (57.5%), and received the HMII as BTT (87.7%). Mean age was 56.6±11.4 years, mean LV ejection fraction was 18.4±7.2%, and the median support time was 217 days (range, 1-952). The majority of patients had an ICD (78.3%), and nearly half (45.3%) had a history of pre-LVAD VAs. All patients were of New York Heart Association class III to IV and INTERMACS level 1 to 4 at the time of HMII implant.
Post-LVAD outcomes are shown in Table 2 . Twenty-one patients died (19.8%), 60 survived to transplantation (56.6%), 3 had the HMII explanted because of myocardial recovery (2.8%), 19 reached the end of follow-up (17.9%), and 3 patients were followed up at other centers after implantation (2.8%). Nonsurgical bleeding and LVAD-related infection were the most common complications, occurring in approximately one third of patients.
Ventricular Arrhythmias
Out of 106 patients, 37 patients (34.9%) developed VAs. Patients with post-LVAD VAs were more likely to have their HMII implanted as DT and to be taking AADs other than amiodarone at the time of implantation (Table 3) . Otherwise, there were no significant differences between the 2 groups. There were a total of 109 episodes of VA, with a median time to first episode of 7 days (range, 1-654; Table 4 ). While 67.6% of the patients with post-LVAD VA had early VA, 51.4% of the patients also had VAs >30 days after HMII implant. Four (10.8%) patients had VAs >1 year after implant. There were no significant clinical differences between those with late VA and those with only early VA. VAs were typically fast, with a mean cycle length of 303.9±111.5 ms. Only 1 episode (0.9%) was suspected to be because of an LVAD suction event.
Clinical Presentation of VAs
The clinical presentation of each VA episode was not documented for many of the episodes, but the available presentations are shown in Table 4 . Twenty-eight percent of episodes were asymptomatic, but 20.2% resulted in symptoms such as palpitations, lightheadedness, or dyspnea. Seventeen VA episodes (15.9%) resulted in hypotension or decreased LVAD flows, and 3 (2.8%) episodes resulted in syncope or altered mental status secondary to low output. Hemodynamically significant episodes of VA had more rapid cycle lengths compared with hemodynamically stable episodes (258.6±91.9 versus 364.6±119.8 ms, respectively [P=0.004]). There were no episodes of sudden cardiac death. One patient had a ventricular fibrillation arrest and was unable to be resuscitated in the setting of mixed cardiogenic/septic shock requiring pressors and multiple broad-spectrum antibiotics. Although ventricular fibrillation was the immediate cause of death, sepsis was the underlying cause of her demise.
Treatment of VAs
More than half (52.3%) of the VA episodes required the use of AADs in the acute setting. Amiodarone was used in nearly all of these cases (94.7%), and lidocaine was the next most commonly used agent (42.1%). Eighteen patients (48.6%) were maintained on AADs as outpatients after presenting with VAs.
In addition, >70% of VA episodes required cardioversion: 60.6% electrical and 10.1% pharmacological. Table 5 ).
Predictors of Post-LVAD VAs
Post-LVAD VAs and Mortality
For the analysis of outcomes, only patients surviving >30 days after HMII implantation were included (98 patients). Out of the 8 patients excluded, 6 died (4 from right heart failure and cardiogenic shock, 1 from septic shock, and 1 from respiratory failure), 1 received a heart transplant, and 1 patient was followed up at another center after discharge. Of the 6 deaths, only 1 patient had VA, and this patient remained in cardiogenic shock after LVAD implantation and died on postoperative day 1. Figure A shows the Kaplan-Meier survival curves for patients with and without post-LVAD VA. Post-LVAD VAs were not associated with increased mortality (HR, 0.58; CI, 0.18-1.90; P=0.353). They were also not associated with increased hospitalizations for CHF (OR, 1.57; CI, 0.56-4.44; P=0.394). 
ICDs and Mortality
Before LVAD implantation, 74 (75.5%) patients had an ICD, and 24 (24.5%) patients did not have an ICD. Post-LVAD, there were 62 (63.3%) patients in the ICD group: 58 had a preexisting ICD, and 4 had a new ICD implanted for post-LVAD VAs. There were 36 (36.7%) patients in the no ICD group: 20 patients did not have an ICD pre-LVAD because of rapidly progressive heart failure (most often postmyocardial infarction), 11 patients had their ICD deactivated for inappropriate or recurrent shocks in the setting of hemodynamically stable VAs, and 5 had their ICD explanted for infective endocarditis. Compared with patients in the no ICD group, those with an ICD were more likely to have a nonischemic cardiomyopathy, have been diagnosed with CHF for >1 year, have a larger LV end-diastolic diameter, and be INTERMACS level 3 or 4 at the time of HMII implantation (Table 6 ). There was no significant difference in LVAD complications such as bleeding between the 2 groups. An ICD shock was administered to 33.8% of patients with an ICD, with 21 (27.3%) patients receiving an appropriate shock and 10 (13.0%) patients receiving an inappropriate shock (Table 4 
Discussion
Our study has 2 primary findings. First, VAs are common in patients with a cfLVAD, occurring in more than one third of patients, but they are not associated with increased mortality. Second, although a significant proportion of these patients receive appropriate therapy, ICDs are not associated with improved survival in this population. To our knowledge, this is the largest study examining VAs and the role of ICDs in patients with a cfLVAD and the first study to suggest that ICDs may not reduce mortality in patients with an LVAD.
In addition to the underlying cardiac pathology of patients with traditional heart failure, patients with an LVAD are at high risk for VAs due to apical scarring around the inflow cannula and arrhythmias from suction events because of LV underfilling or high pump speed. In our study, 34.9% of patients experienced post-LVAD VAs, and this incidence is consistent with previous studies. [4] [5] [6] [7] [8] LVAD suction was thought to be the cause of VA in only 1 of the patients, and VAs ceased after the pump speed was decreased. Although the majority of VA episodes occurred in the first 30 days after HMII implantation, more than half of the patients had late VAs, highlighting that these patients remain at risk after their index hospitalization. The use of AADs other than amiodarone pre-LVAD was the only independent predictor of post-LVAD VAs in our study. Previous studies in patients with a cfLVAD had shown that pre-LVAD VAs were predictive of post-LVAD VAs. 6, 7 Although there was a trend for this (OR, 1.46), it was not statistically significant in our study.
VAs in patients with an LVAD often result in presentation to a hospital, 11 but the clinical consequences of these episodes are not reported extensively in the literature. In a study of 61 patients with the HMII, around one third of patients had palpitations or dyspnea with VAs, 18% had signs of right heart failure (nausea, edema), and 7% of patients had syncope. 6 In our study, many VA episodes had rapid rates, resulted in symptoms of hypotension and decreased LVAD flows, and required AADs and electrical cardioversion for termination. However, there were notably no episodes of sudden cardiac death.
The effect of VAs on mortality in patients with a cfLVAD has been variable in the literature. A study by Brenyo et al 7 examining 61 ambulatory patients with a cfLVAD and an ICD showed that ICD treatment for post-LVAD VAs was independently associated with an increase in mortality (HR, 9.69; 95% CI, 2.6-36.0; P=0.001). However, in another study of 61 patients with the HMII, Raasch et al 6 showed that patients with post-LVAD VAs did not have significantly different rates of survival or survival to transplantation. The results of our study are consistent with those of Raasch et al, 6 and it is plausible that post-LVAD VAs do not significantly influence mortality. The incidence of sudden cardiac death is very low, and many VA episodes are well tolerated. Moreover, even with hemodynamically significant episodes, patients are able to reach medical professionals for appropriate treatment.
The data on the effectiveness of ICDs in patients with an LVAD are sparse. To our knowledge, there are only 2 retrospective studies published examining the impact of ICDs on mortality, and each study consisted predominantly of patients with pulsatile LVADs. The largest study was done by Cantillon et al 12 at the Cleveland Clinic. It had 478 patients, but only 39 (8.2%) patients had cfLVADs. They showed that ICDs conferred an independent mortality benefit (HR, 0.55; 95% CI, 0.32-0.94; P=0.028). Refaat et al 13 studied 144 patients with biventricular assist devices or LVADs as BTT, and there were no patients with cfLVADs. An ICD was associated with increased survival to transplantation (OR, 2.72; 95% CI, 1.03-7.16; P=0.04). In each of these studies, patients with an ICD were more likely to have been diagnosed with CHF earlier and have larger left ventricular end-diastolic diameters compared with patients without an ICD. It is possible that ICDs did not actually confer a survival benefit but were simply markers of more stable patients with less progressive forms of heart failure and a better prognosis.
In our study, an active ICD was not associated with improved survival. As in the other studies, patients with ICDs were more likely to have been diagnosed with CHF for >1 year, have larger left ventricular end-diastolic diameters, and be INTERMACS level 3 to 4 at the time of HMII implantation. Therefore, this result is even more remarkable because although patients with an ICD were less sick at the time of implant than those without one, they still did not have improved survival. Appropriate shocks were received by 27.3% of patients, while 13.0% experienced an inappropriate shock. This is consistent with the burden of ICD therapy reported in previous studies of patients with a cfLVAD, with appropriate and inappropriate shocks occurring in 16% to 41% and 6% to 25%, respectively. [4] [5] [6] [7] However, appropriate shocks were not associated with increased mortality in our study. Although this is contrary to 2 previous studies, 7, 14 our results are reasonable. Patients with the HMII are largely protected from the negative inotropic effects of shocks, and VAs were not associated with increased hospitalizations for heart failure in our study.
Our findings may have implications for the management of VAs in patients with cfLVADs. First, some centers have advocated placing an ICD in patients without one after LVAD implantation. 15 The presence of an LVAD changes the natural history of survival in advanced heart failure, and our analysis suggests that the presentation of fast VAs may be favorably altered by the hemodynamic support of an LVAD. Thus, it may not be cost-effective to implant ICDs, especially in patients with an LVAD as BTT. Second, one third of patients with the HMII will experience an ICD shock, and many patients will experience multiple shocks. Psychosocial distress, particularly anxiety and post-traumatic stress disorder, occurs in 13% to 38% of patients with an ICD, 16 and ICD discharges have been shown to decrease the quality of life substantially in patients with an ICD. 17, 18 Given the significant morbidity associated with ICD shocks and the questionable benefit in this patient population, consideration may be given to inactivating ICDs in patients receiving multiple shocks for hemodynamically stable VAs.
Limitations
Our study has several important limitations. First, this study is a retrospective, nonrandomized study subject to selection bias and confounding. In addition, there were a relatively small number of patients with a small number of outcomes, and thus it is limited in power to detect small differences. Because of this, our findings should be considered only exploratory and hypothesis generating. Second, because of the retrospective nature of the study, the data were limited by what was documented in the chart. As a result, the true incidence of post-LVAD VAs was likely underestimated, and the clinical presentations of VA episodes were incomplete. Nevertheless, the ICD status and outcome of each patient were ascertained. Third, the generalizability of our results is somewhat limited. More than 85% of the patients in our study had the HMII implanted as a bridge to transplant. It is important to note that ICDs may have a different clinical impact in patients with DT LVADs because the duration of support is longer and because it seems that these patients remain at risk for VAs >1 year after implantation. Finally, this was a single-center study containing only patients with the HMII. Although we did not include patients supported with the other commercially available cfL-VAD (HeartWare), we expect that our findings are generalizable but cannot be certain.
Conclusions
This is the largest published study examining VAs and the role of ICDs in patients with a cfLVAD. VAs are common in patients with cfLVADs, but post-LVAD VAs are not associated with increased mortality. Correspondingly, an active ICD is not associated with improved survival and may not reduce mortality in these patients despite frequent appropriate therapy for VAs. Randomized trials in both BTT and DT patients would be needed to confirm our findings.
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CLINICAL PERSPECTIVE
Continuous flow left ventricular assist devices extend survival and improve quality of life for patients with advanced heart failure. Most experience early and sustained improvements in functional capacity, whereas others remain limited by adverse events including infection, right heart failure, and nonsurgical bleeding. Ventricular arrhythmias (VA) occur in as many as 20% to 50% of recipients of continuous flow left ventricular assist device, with the majority of episodes arising within 1 month of device implantation. The degree to which continuous flow left ventricular assist devices maintain pump output when the heart experiences VA varies. Some patients experience a symptomatic reduction in cardiac output, whereas others tolerate extended episodes of VA without any adverse outcome. Because continuous flow left ventricular assist devices may favorably alter the natural history of such arrhythmias, the impact of VAs on mortality, and therefore the clinical use of implantable cardioverter-defibrillators, in these patients is uncertain. In our single-center, retrospective analysis, we report that roughly one third of patients experienced VA. Most events were rapid ventricular tachycardia requiring electrical or chemical cardioversion. Only 28% of patients remained asymptomatic. No patient experienced sudden cardiac death. There was no observed difference in survival between those patients with an active implantable cardioverter-defibrillator and those without. If validated in a larger series or prospective trial, these results may assist patients in their shared decision making. Those with implantable cardioverter-defibrillators may choose to inactivate them, eliminating their exposure to potentially unnecessary and uncomfortable defibrillator shocks. Others without an implantable cardioverter-defibrillator may choose not to have one implanted. The cost-effectiveness of combining these 2 expensive, albeit life-saving, therapies should be explored.
